# Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities

> **NCT06794996** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 42 (actual)

## Conditions studied

- Proteinuric Kidney Disease

## Interventions

- **DRUG:** Inaxaplin

## Key facts

- **NCT ID:** NCT06794996
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-02-04
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06794996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06794996, "Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06794996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*